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Background: Thymoma is associated with various paraneoplastic autoimmune disorders. Herein, we report
paraneoplastic neuromyelitis optica (NMO) associated with both anti-aquaporin-4 (AQP4) immunoglobulin G (IgG)
and type 1 antineuronal nuclear antibody (ANNA-1) in an invasive thymoma patient.
Case presentation: A woman presented with a sudden onset of bilateral progressive visual loss associated with
recurrence of invasive thymoma, 6 years after thymectomy and immunosuppressive treatment. AQP4-IgG and
ANNA-1 were present in the patient’s serum. Visual outcome was poor despite immunosuppressive treatment.
Longitudinally extensive transverse myelitis developed 27 months after the onset of visual symptoms.
Conclusions: We have reported a case of paraneoplastic NMO associated with both AQP4-IgG and ANNA-1
autoantibodies in an invasive thymoma patient.
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Thymoma is associated with various paraneoplastic auto-
immune disorders [1]. However, there has been no report
of paraneoplastic neuromyelitis optica (NMO) associated
with both anti-aquaporin-4 (APQ4) immunoglobulin G
(IgG) and type 1 antineuronal nuclear antibody (ANNA-1)
in an invasive thymoma patient. We found a patient with
invasive thymoma who developed bilateral progressive vis-
ual loss and showed circulating APQ4-IgG and ANNA-1
autoantibodies. Lower extremity weakness and tingling
sense developed 27 months after the onset of visual symp-
toms, and she was finally diagnosed as definite NMO.Case presentation
A 55-year-old woman showed a sudden onset of painless
progressive vision loss in her right eye for 1 week. Six years
ago, she underwent thymectomy for invasive thymoma
(WHO classification B2) followed by chemotherapy (adria-
mycin, cisplatin, vincristine, and cyclophosphamide) and
radiation therapy. The thymoma had completely regressed* Correspondence: hjm@snu.ac.kr
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were detected during follow-up examinations.
On ocular examination, her visual acuities were hand
motion in the right eye and 20/20 in the left eye, with a
relative afferent pupillary defect in the right eye. The an-
terior segment and media of both eyes were normal. In-
traocular pressure of both eyes were 14 mmHg. Ocular
motility was normal without any pain during extraocular
muscle movements. Ptosis or exophthalmos were absent
in either eye. Fundus examinations of the optic disc and
retina were unremarkable. She could not recognize the
demonstration plate of Ishihara color vision test and any
of the Hardy, Rand, and Rittler (HRR) color vision test
with the right eye, but could recognize all of the Ishihara
color vision test and HRR color vision test with the left
eye. Goldmann perimetry showed a small nasal island in
the right eye. Magnetic resonance imaging (MRI) re-
vealed an abnormal contrast-enhancement of the right
optic nerve extending to the prechiasmatic portion, sug-
gesting an acute inflammatory or demyelinating process
(Figure 1). No treatment was administered owing to the
patient’s refusal. After 2 months, visual acuity and visual
field defects of the right eye showed a further gradual
deterioration without recovery and the patient was lost
to follow-up.d. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Figure 1 Brain magnetic resonance imaging 1 week after clinical onset of visual loss in the right eye. Axial fat saturated T1-weighted
imaging (T1WI) (A) and contrast-enhanced T1WI (B) shows enhancement of the intraorbital portion of the right optic nerve (white arrow).
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presenting with a sudden onset of visual acuity decrease
in the left eye for 1 week. In the right eye, she had visual
acuity of light perception, and the visual acuity of the left
eye had reduced to 20/30 from 20/20. Color vision tests
revealed a moderate red-green and blue-yellow color de-
fect in the left eye. Visual field testing revealed a general-
ized reduction of sensitivity and a cecocentral scotoma in
the left eye. The anterior segment and media of both eyes
were normal. Funduscopy showed total pallor of the optic
disc in the right eye, but a normal optic disc without
edema or pallor in the left eye. Visual evoked potentials
were delayed in both eyes. MRI of the orbit and brain re-
vealed high signal intensities of both optic nerves on T2-
weighted images and increased abnormal enhancement of
the right optic nerve extending to the prechiasmatic por-
tion. However, there was no evidence of brain metastasis
or cerebrospinal fluid (CSF) seeding.
Systemic evaluation was performed to investigate the
presence of malignancy; chest computed tomography
(CT) revealed a 4.7-cm nodule in the left lower lobe and
lung biopsy confirmed the diagnosis of a malignant epi-
thelial neoplasm with cytokeratin expression, no epithe-
lial membrane antigen, no CD5 expression, and no
neuroendocrine marker expression. It was histopatho-
logically similar to her prior thymoma and the possibility
of recurrent thymoma was considered. Whole body posi-
tron emission tomography showed no other areas of
abnormal hypermetabolic lesions. Serological examin-
ation for major paraneoplastic autoantibodies revealed
the presence of APQ4-IgG and ANNA-1, while anti-Yo
antibody, ANNA-2, anti-Ri, anti-acetylcholine receptor
antibodies, anti-recoverin, anti-alpha-enolase, and anti-
collapsin response-mediator protein-5 (CRMP5) anti-
bodies were absent. Blood analysis, including erythrocyte
sedimentation rate, C-reactive protein, thyroid function
tests, and angiotensin-converting enzyme levels were
within normal range, and tumor markers (CEA, CA19-9,and CA125) were absent. Microbiological tests were
negative for varicella zoster virus, cytomegalovirus, Epstein-
Barr virus, syphilis, and HIV. Antinuclear antibody, anti-
double stranded DNA and anticardiolipin antibodies were
negative. Cytological examination of the CSF showed no
abnormal findings, including oligoclonal bands. Primary
mutations for Leber’s hereditary optic neuropathy of
11778/ND4, 3460/ND1, 14484/ND6 and 4171/ND1 were
absent.
On the basis of the clinical presentation, neuroimag-
ing, and presence of autoantibodies, her condition was
diagnosed as NMO spectrum disorder associated with
invasive thymoma. Intravenous methylprednisolone was
administered, followed by oral prednisolone (60 mg) and
oral cyclosporine (600 mg) daily for 2 weeks. However,
her visual acuities continuously deteriorated to no light
perception in the right eye and counting fingers in the
left eye. After 6 weeks of onset in her left eye, optical co-
herence tomography showed diffuse atrophy of the ret-
inal nerve fiber layers in both eyes, but the outer retina
and photoreceptor layers were relatively intact. Standard
electroretinograms (ERG) were normal in both eyes, but
multifocal ERG (mfERG) showed a decreased response
in the macula of both eyes. Follow-up MRI examination
revealed increased abnormal enhancement of the left
optic nerve. The patient received 6 cycles of chemother-
apy with etoposide, paclitaxel, and prednisolone over the
next 6 months and was maintained with azathioprine.
The left lower lung mass had regressed on follow-up
chest CT; however, visual acuities were unchanged. No
evidence of tumor recurrence or neurologic signs of
limb weakness and sensory abnormalities occurred up to
13 months after chemotherapy, when suddenly, she devel-
oped symptoms of lower limb weakness and tingling
sense. Neurologic examination revealed proximal domin-
ant weakness in both lower extremities of grade 4. Tin-
gling sense below sensory level T10 developed with pain/
temperature, vibration and positional sense hypesthesia.
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verse myelitis with central T2 high signal intensity of the
spinal cord from level T3/4 to T11. She was diagnosed as
definite NMO and her myelitis improved after administra-
tion of intravenous methylprednisolone.
Discussion
Thymoma has been associated with several immunologic-
ally mediated diseases, and various paraneoplastic auto-
antibodies [1]. Although rare, thymoma associated with
visual symptoms has been reported in association with
paraneoplastic autoantibodies, such as cancer-associated
retinopathy (CAR) with anti-retinal antibodies, paraneo-
plastic optic neuropathy (PON) with anti-CRMP5 anti-
body, or NMO with AQP4-IgG [2]. However, there has
been no report of the combined presence of APQ4 and
ANNA-1 autoantibodies. Our patient showed predomin-
ant involvement of the retinal ganglion cells associated
with severe retinal nerve fiber layer thinning, while the
outer retina and photoreceptor layers were relatively in-
tact. Standard ERG were normal in both eyes. MfERG re-
sponses were slightly depressed in the center. However,
for patients with poor fixation, the accuracy of mfERG re-
sults may be difficult to interpret [3]. Particularly, central
mfERG amplitudes are most affected by unsteady fixation
as in our patient. Therefore, there was no evidence to
suspect retinal abnormalities [3]. The abnormal contrast-
enhancement of the optic nerve on MRI suggested an
inflammatory or demyelinating pathology.
APQ4-IgG is known to be highly specific for NMO
with specificity reported up to 94% [4]. An earlier study
conducted before the discovery of APQ4-IgG has re-
ported central nervous system and thymic epithelial
cell–specific antibodies in a patient with thymoma and
myasthenia gravis during the acute phase of NMO, sug-
gesting that the NMO was linked to the thymoma [5].
Transverse myelitis developed 2 years after the onset
of visual loss, which is not typical for definite NMO his-
torically with a monophasic course of bilateral optic
neuritis and myelitis with short intervals between the
index events [4]. The long interval between events may
be attributed to the long-term immunosuppression and
chemotherapy that may have decreased APQ4-IgG titers,
thus preventing further relapse or development of myeli-
tis during the course of the disease. Weinshenker et al
[6] have reported the importance of serum AQP4-IgG in
the disease progression of NMO patients, and suggested
that immunosuppressive treatment may lessen the chance
of a second or subsequent attack of transverse myelitis
even before the clinical criteria for NMO are satisfied.
On the other hand, Matiello et al [7] have shown that
after a median of 9 years of follow-up, 50% of APQ4-
IgG seropositive patients with initial optic neuritis may
experience an episode of myelitis and fulfill the criteriaof denite NMO. Therefore, a longer follow-up for sev-
eral years may reveal a subsequent myelopathy as in our
case. A long-term follow-up of serum autoantibodies as
well as serial neurologic examinations is warranted in
such cases.
The clinical significance of APQ4-IgG associated with
cancer is unclear. APQ4-IgG was found to be associated
with cancer in 0.004% of cases, including 1 thymoma pa-
tient screened for paraneoplastic autoantibodies [8]. Six of
these patients had NMO spectrum disorders before or after
cancer detection (3–18 months), whereas 2 did not have
any neurological evidence of an NMO spectrum disorder
[8]. A previous study has also reported serum positive
APQ4-IgG in a patient with possible paraneoplastic NMO
associated with lung cancer [9]. Therefore, the clinical util-
ity of this autoantibody as a cancer marker warrants pro-
spective investigation.
ANNA-1 is recognized as an IgG marker for small-cell
lung carcinoma, and has rarely been found in thymoma
patients with neurologic autoimmunity. The oncologic
implication of ANNA-1 seropositivity has been shown in
a previous report of 172 thymoma patients, where 3% of
cases were positive for ANNA-1 [10]. However, isolated
visual symptoms have not been reported with ANNA-1,
and thus it may not be directly related to optic neur-
opathy. The presence of paraneoplastic NMO-associated
serum APQ4-IgG alone may lead to a poor visual progno-
sis which is refractory to immunosuppressive treatment.
Thus, the implication of the coexistence of ANNA-1 re-
mains to be elucidated.
Conclusion
Thymoma could be associated with paraneoplastic NMO
with both APQ4-IgG and ANNA-1 autoantibodies.
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